RATIONALE: Twelve million people develop ischemic stroke each year world over and 30-40% of them do not have arterial occlusions at presentation. Trials conducted to study the efficacy of thrombolytic drug reported better outcome with use of thrombolytic drug but none studied the subtypes of ischemic strokes specifically and adequately. The subgroups of patients with no arterial occlusion at presentation continue to receive thrombolytic therapy without proven benefit and with some risk. AIM: The aim of this article is to study whether intravenous thrombolysis with alteplase improves clinical outcome in ischemic stroke patients who do not have arterial occlusion at presentation. DESIGN: A retrospective medical record-based observational multicenter, multinational study. OUTCOMES: Primary outcome measure would be clinical outcome at three-months from stroke onset measured by modified Rankin Scale and National Institute of Health Stroke Scale. Secondary outcome measure will be frequency of intracerebral hemorrhage causing worsening of clinical deficit defined as increase in National Institute of Health Stroke Scale by >4.
RATIONALE: Twelve million people develop ischemic stroke each year world over and 30-40% of them do not have arterial occlusions at presentation. Trials conducted to study the efficacy of thrombolytic drug reported better outcome with use of thrombolytic drug but none studied the subtypes of ischemic strokes specifically and adequately. The subgroups of patients with no arterial occlusion at presentation continue to receive thrombolytic therapy without proven benefit and with some risk. AIM: The aim of this article is to study whether intravenous thrombolysis with alteplase improves clinical outcome in ischemic strokepatients who do not have arterial occlusion at presentation. DESIGN: A retrospective medical record-based observational multicenter, multinational study. OUTCOMES: Primary outcome measure would be clinical outcome at three-months from stroke onset measured by modified Rankin Scale and National Institute of Health Stroke Scale. Secondary outcome measure will be frequency of intracerebral hemorrhage causing worsening of clinical deficit defined as increase in National Institute of Health Stroke Scale by >4.
Authors: Timothy John Ingall; William Michael O'Fallon; Kjell Asplund; Lewis Robert Goldfrank; Vicki S Hertzberg; Thomas Arthur Louis; Teresa J Hengy Christianson Journal: Stroke Date: 2004-09-02 Impact factor: 7.914
Authors: W Hacke; M Kaste; C Fieschi; R von Kummer; A Davalos; D Meier; V Larrue; E Bluhmki; S Davis; G Donnan; D Schneider; E Diez-Tejedor; P Trouillas Journal: Lancet Date: 1998-10-17 Impact factor: 79.321
Authors: J P Mohr; L R Caplan; J W Melski; R J Goldstein; G W Duncan; J P Kistler; M S Pessin; H L Bleich Journal: Neurology Date: 1978-08 Impact factor: 9.910
Authors: W Hacke; M Kaste; C Fieschi; D Toni; E Lesaffre; R von Kummer; G Boysen; E Bluhmki; G Höxter; M H Mahagne Journal: JAMA Date: 1995-10-04 Impact factor: 56.272
Authors: Alex Förster; Hans Ulrich Kerl; Holger Wenz; Marc A Brockmann; Ingo Nölte; Christoph Groden Journal: PLoS One Date: 2013-10-10 Impact factor: 3.240